The Omniscient Regulator: QRxPharma’s Unusual Take on FDA and Investor Calls
This article was originally published in RPM Report
Executive Summary
Investor calls routinely begin with a disclaimer that the call is being recorded. They don’t usually include a warning that “FDA is monitoring the call.” But that is how QRxPharma began a discussion of a bad news event for its MoxDuo application.